Table 2.
Allelic and genotypic frequencies of the target RGMa promoter SNPs in enrolled patient group and healthy subject group.
|
CHS from 1,000 genome (n = 108) |
Enrolled patients group (n = 201) |
p -value | |
|---|---|---|---|
| rs4778099 (allele and genotype frequency) | |||
| A | 70 (32.4%) | 131 (32.6%) | 0.964 |
| G | 146 (67.6%) | 271 (67.4) | |
| AA | 10 (9.3%) | 23 (11.4%) | 0.732 |
| AG | 50 (46.3%) | 85 (42.3%) | |
| GG | 48 (44.4%) | 93 (46.3%) | |
| rs10520720 (allele and genotype frequency) | |||
| A | 34 (15.7%) | 63 (15.7%) | 0.982 |
| G | 182 (84.3%) | 339 (84.3%) | |
| AA | 2 (1.8%) | 4 (2.0%) | 0.994 |
| AG | 30 (27.8%) | 55 (27.4%) | |
| GG | 76 (70.4%) | 142 (70.6%) | |
| rs725458 (allele and genotype frequency) | |||
| T | 135 (62.5%) | 247 (61.4%) | 0.796 |
| C | 81 (37.5%) | 155 (38.6%) | |
| TT | 43 (39.8%) | 77 (38.3%) | 0.965 |
| TC | 49 (45.4%) | 93 (46.3%) | |
| CC | 16 (14.8%) | 31 (15.4%) | |
CHS, Han population in Southern China.